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Irritable bowel syndrome (ibs) is a disorderwhich manifests as a set of chronic gastrointestinal (GI) symptoms and changes in bowel habits in the 
absence of evident structural and biochemical abnorm- 
alities.1,2 Overall, IBS is the most commonly diagnosed 
GI disorder with a global prevalence of 10–15% and is 
more frequent among individuals aged <50 years old.3,4 
Altered bowel habits are the most commonly reported 
clinical feature, with the syndrome predominantly 
associated with constipation (IBS-C), diarrhoea (IBS-D) 
or a mixture of both conditions (IBS-M).1 In addition, 
patients with IBS often experience abdominal pain, 
which can be provoked by emotional stress or eating 
and is usually alleviated by the passing of stool.1,2
A diagnosis of IBS is confirmed according to 
the latest version of the Rome criteria based on the 
clinical experience and consensus of a committee of 
multinational experts.2,5–7 The role of radiological 
imaging in the diagnosis of IBS is still limited to those 
patients with ‘red flag’ symptoms, such as rectal 
bleeding, iron-deficiency anaemia and weight loss, in 
order to exclude other underlying diseases.8 However, 
a recent study indicated that diffusion-weight imaging 
can accurately assess disease activity among patients 
with Crohn’s disease, a GI condition with similar 
symptoms to IBS.9 
Despite extensive research, the typical mechanistic 
pathways of IBS have not yet been clearly elucidated. It 
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فعالية وسالمة الربوبيوتيك والربيبايوتك والسينوبيوتيك يف عالج متالزمة القولون املتهيج
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abstract: Treatments that target alterations in gut microbiota may be beneficial for patients with irritable 
bowel syndrome (IBS). A systematic review and meta-analysis was conducted of randomised clinical trials (RCTs) 
evaluating the efficacy and safety of probiotics, prebiotics and synbiotics. Factors considered in the analysis 
included global IBS symptoms and/or abdominal pain, secondary symptoms and the frequency of adverse events. 
A total of 33 RCTs involving 4,321 patients were identified. Overall, probiotics significantly improved global IBS 
symptoms compared to placebos (standardised mean difference = −0.32, 95% confidence interval: −0.48 to −0.15; 
P <0.001), with significant heterogeneity between studies (I2 = 72%; P <0.001). This remained apparent in both 
single- and multi-strain probiotic interventions as well as synbiotic formulations. However, evidence regarding 
prebiotics was scarce. There were no significant inter-group differences in terms of the frequency of adverse events. 
Future RCTs should address methodological limitations, including short follow-up periods and patient adherence.
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امللخ�ص: قد تكون العالجات التي ت�صتهدف التغيريات يف ميكروبات الأمعاء مفيدة للمر�صى الذين يعانون من متالزمة القولون املتهيج. 
اأجريت هذه املراجعة املنهجية والتحليل البعدي للتجارب ال�رشيرية الع�صوائية وذلك لتقييم فعالية و�صالمة الربوبيوتيك والربيبايوتيك 
وال�صينوبيوتيك. و�صملت العوامل التي مت النظر فيها يف التحليل اأعرا�س القولون املتهيج ال�صامل و/اأو اأمل يف البطن والأعرا�س الثانوية 
4,321 مري�صا. وعموما، ح�صنت  33 من التجارب ال�رشيرية الع�صوائية التي �صملت على  وتكرار الأحداث ال�صلبية. مت حتديد ما جمموعه 
الثقة٪:  %95 فا�صل   ،-0.32 )فرق متو�صط موحد =  ال�صامل مقارنة مع الغفل  القولون املتهيج  اأعرا�س  الربوبيوتيك ب�صكل ملحوظ من 
تدخالت  من  كل  يف  وا�صحا  هذا  ظل   .)I2  =  72% P؛   >0.001( الدرا�صات  بني  كبري  جتان�س  عدم  مع   ،)P  >0.001 0.15-؛  اإىل   -0.48
الربوبيوتيك الأحادية ومتعددة ال�صاللت وكذلك يف تركيبات ال�صينوبيوتيك. ومع ذلك، فاإن الأدلة املتعلقة بالربيبايوتك كانت نادرة. مل 
تكن هناك اختالفات كبرية بني املجموعات من حيث تواتر الأحداث ال�صلبية. ينبغي اأن تعالج التجارب ال�رشيرية الع�صوائية يف امل�صتقبل 
القيود املنهجية، مبا يف ذلك فرتات املتابعة الق�صرية والتزام املري�س.
الكلمات املفتاحية: متالزمة القولون املتهيج؛ ميكروبيوم اجلهاز اله�صمي؛ املكمالت الغذائية؛ الربوبيوتيك؛ الربيبايوتك�س؛ ال�صينوبيوتيك؛ 
التحليل البعدي؛ مراجعة منهجية.
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has been postulated that enteric infections, immuno- 
modulation, visceral hypersensitivity and an imbalance 
in neurotransmitters may all play a role in the devel- 
opment of IBS.10–12 Importantly, alterations in the gut 
microbiota can induce changes in gut motility, permea- 
bility, food processing and visceral perception which 
eventually leads to the occurrence of IBS-related 
symptoms.13,14 Multiple studies have shown that IBS 
patients experience bacterial overgrowth in the small 
intestine or altered GI microbes.15–18 A recent meta-
analysis observed that patients with IBS (particularly 
IBS-D) have significantly reduced GI colonies of 
Bifidobacterium, Lactobacillus and Faecalibacterium 
prausnitzii bacteria compared to healthy individuals.19 
Furthermore, the link between GI microbial disruption 
and IBS is corroborated by the fact that 10–53% of 
patients are diagnosed with IBS following a GI infection.20
Such findings have opened a new avenue of 
treatment to control IBS symptoms, namely the 
manipulation of gut microbiota. Potential therapies to 
modulate the microbial composition of the GI envir- 
onment include dietary supplements incorporating 
prebiotics, probiotics or synbiotics. Prebiotics are non- 
digestible dietary compounds that stimulate the growth 
and activity of specific bacterial populations, while 
probiotics are live microorganisms that can be supple- 
mented in adequate amounts to induce therapeutic 
benefits.21 Synbiotics, the combination of both prebiotics 
and probiotics, can provide beneficial effects to the 
host and improve the viability of its constituents.22 
Nevertheless, the effects of such therapeutic approaches 
in the treatment of IBS are questionable, particularly 
with regards to using single or several variations or 
combinations of probiotics and prebiotics. Therefore, 
a comprehensive evaluation of the efficacy and safety 
of prebiotics, probiotics and synbiotics in the manage- 
ment of patients with IBS is necessary.
Methods
All procedures were conducted according to the 
standards of the Preferred Reporting Items for Syst- 
ematic Reviews and Meta-Analyses.23 Only prospective 
randomised clinical trials (RCTs) published in English-
language peer-reviewed journals between 2000 and 
2019 that compared the effects of prebiotics, probiotics 
and synbiotics on adult IBS patients (aged ≥18 years) 
were included in the analysis. Trials including children 
or patients with other GI disorders were excluded. 
The diagnosis of IBS was confirmed according to any 
version of the Rome criteria in order to ensure minimal 
heterogeneity if other diagnostic criteria or basic physician 
opinions were used initially.2,5–7
In order to be eligible for inclusion, the RCTs had 
to involve the administration of at least one of three 
therapeutic interventions (prebiotics, probiotics and/
or synbiotics) to a specific cohort of IBS patients and 
compare outcomes with another group receiving a 
placebo. The minimum sample size was 50 patients. 
Trials using probiotics could include either single- 
or multi-strain preparations. If a trial incorporated 
multiple intervention groups with different doses, 
the group with the highest dose was included in the 
analysis in order to avoid any overlap that might result 
from multiple analyses of placebo outcomes. Trials 
employing a cross-over design were excluded.24 In 
addition, narrative reviews, case reports, conference 
proceedings, retrospective studies and systematic 
reviews were excluded.
The primary outcomes of the meta-analysis 
included the efficacy of the therapeutic interventions 
on global IBS symptoms and/or abdominal pain. These 
outcomes were presented as continuous variables in 
terms of mean differences in scores at the end of the 
follow-up period. Additionally, secondary outcomes 
included the effects of the interventions on the scores 
of other symptoms (i.e. bloating/distension, flatulence 
and urgency), along with impact on quality of life 
(QOL). In terms of safety, the reported frequencies of 
adverse events at the end of the follow-up period were 
analysed.
A comprehensive literature search was performed 
of various databases, including MEDLINE® (National 
Library of Medicine, Bethesda, Maryland, USA), Embase 
(Elsevier, Amsterdam, The Netherlands) Cochrane Library 
(Cochrane, London, UK) and Google Scholar (Google 
LLC, Mountain View, California, USA). The search was 
conducted in June 2019 using the following keywords 
combined as appropriate using Boolean operators (e.g. 
“or” and “and”): “irritable bowel syndrome”, “irritable 
bowel”, “probiotic”, “Bacillus”, “Bifidobacterium”, “Lacto- 
bacillus”, “Streptococcus”, “Enterococcus”, “Propioni- 
bacterium”, “Saccharomyces”, “Clostridium”, “synbiotic”, 
“prebiotic”, “fructooligosaccharide”, “inulin”, “randomized/ 
randomised” and “trial”. 
Two researchers independently screened the titles 
and abstracts of identified articles to determine their 
eligibility for inclusion in the analysis. The reference 
lists of the articles were also screened for any additional 
publications. Any disagreements concerning eligibility 
were discussed until a consensus was reached. Information 
concerning all eligible articles was uploaded to a ref- 
erence management software (EndNote, Version X7, 
Clarivate Analytics, Philadelphia, Pennsylvania, USA) 
to check for any potential duplication. Subsequently, 
all non-full-text articles were excluded from the final 
analysis.
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An initial literature search revealed a total of 
3,478 publications across the databases, of which 30 
were duplicates. In addition, seven eligible articles were 
identified from reference lists. After the exclusion of 
3,408 irrelevant publications, a total of 47 full-text RCTs 
were assessed for eligibility. During the assessment, 
14 trials were excluded for various reasons, including 
having <50 patients in both groups, presenting outcomes 
in an uninterpretable manner, employing a 2 × 2 
factorial design with changes in diet, investigating 
QOL as the primary outcome without focusing on IBS 
symptoms, adding simethicone to the intervention or 
for not being written in English. Ultimately, a total of 
33 RCTs were included in the final analysis [Figure 1].
Information concerning each of these RCTs was 
recorded in an Excel spreadsheet, Version 2016 (Microsoft 
Corp., Redmond, Washington, USA). The name of the 
first author, year of publication, country, study duration 
and sample size of the study was recorded as well as 
the gender distribution of the patients and the number 
of patients allocated to the study groups. Regarding 
disease-specific data, the distribution of IBS subtypes, 
version of Rome criteria utilised and data collection 
instrument was noted. In terms of intervention-
related data, the type of intervention (i.e. prebiotic, 
probiotic or synbiotic), use of single- or multi-strain 
probiotics and the dosage and form of the intervention 
was documented, as well as outcome data with regards 
to scores for global IBS symptoms, abdominal pain, 
bloating/distension, flatulence, urgency and QOL 
and the frequency of adverse events at the end of the 
follow-up period.
Each trial underwent quality assessment using the 
Cochrane Risk of Bias Tool which assesses processes 
of random sequence generation and blinding of out- 
comes, participant/personnel data and intervention 
allocation, among other measurements of bias.25 The 
results were presented graphically using RevMan 
software, Version 5.3 (Cochrane), with each domain 
interpreted as being either low-risk, high-risk or unclear. 
With regards to statistical analysis, continuous variables 
(i.e. symptom and QOL scores) were presented as 
standardised mean differences (SMDs) with 95% conf- 
idence intervals (CIs), while dichotomous variables 
(i.e. frequencies of adverse events) were expressed as 
relative risks (RRs) with 95% CIs. Overall effects were 
analysed using z-statistics. Inter-study heterogeneity 
was assessed using the I2 test, with a random effect 
model applied in the event of significant heterogeneity 
(I2 ≥50%). A subgroup analysis was performed based 
on the sample size, type of therapeutic intervention 
and the version of Rome criteria utilised. A P value of 
<0.05 was considered statistically significant. 
Results
The general characteristics of the RCTs are outlined in 
Table 1.26–58 All of the RCTs were published between 
2000 and 2018, with the duration of the intervention 
ranging between 2–24 weeks. Overall, there were 
a total of 4,321 patients with IBS, of which 59.5% 
were female.26–58 In terms of IBS subtypes, six RCTs 
included patients with IBS-D, one with IBS-C and one 
with both IBS-D and IBS-M.26–33 The remaining trials 
included patients with all subtypes.34–58 With regards 
to location, the majority of the trials were conducted 
in Europe (n = 18) followed by Asia (n = 13).26–33,36–58 
The remaining two RCTs were based in South Africa 
and the USA, respectively.34,35 
The Rome I criteria were used for diagnosis in 
two trials, while the Rome II criteria were used in 11 
trials.32–34,40–49 The rest of the trials utilised the Rome 
III criteria.26–31,35–39,50–58 In terms of intervention, three 
trials investigated prebiotics (partially-hydrolysed guar 
gum and fructooligosaccharides) and three investigated 
synbiotics.38,40,42,50,51 The remaining 27 RCTs evaluated 
probiotics.26–37,39,41,43,44,46–49,52–58 Just over half of the 
probiotic trials contained multiple bacterial strains 
(n = 14).29–32,35,37,44,47–49,52–54 The other 13 trials cont- 
ained single strains, comprising of Lactobacillus, Bifi- 
 
Figure 1: Flow chart showing the search process used 
to identify articles included in this study’s systematic 
review and meta-analysis.
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Table 1: Summary of randomised clinical trials assessing the efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable 
bowel syndrome26–58















Intervention Strain or type of intervention Dosage and 
form of 
intervention
Azpiroz et al.51 
(2017)
Spain 4 79 (48/31) I: 41.0 ± 11.1 
P: 42.4 ± 10.6
I: 41 
P: 38
Rome III All Prebiotic FOO Twice daily in 
powder sachets
Niv et al.50 
(2016)
Israel 12 108 (37/71) I: 46.2 ± 19.2 
P: 40.8 ± 15.6
I: 49 
P: 59
Rome III All Prebiotic PHGG Once daily in 
powder sachets
Olesen et al.42 
(2000) 
Denmark 12 63 (11/52) I: 45.1 ± 13.1 
P: 45.1 ± 13.1
I: 30 
P: 32
Rome I All Prebiotic FOO Once daily in 
powder sachets
Abbas et al.27 
(2014)
Pakistan 6 72 (53/19) I: 37.7 ± 11.6 
P: 33.0 ± 12.0
I: 37 
P: 35
Rome III IBS-D Probiotic SS S. boulardii Once daily in 
syrup
Amirimani et al.39 
(2013)
Iran 4 92 (36/56) I: 44.9 ± 13.0 
P: 37.7 ± 10.5
I: 41 
P: 31
Rome III All Probiotic SS L. reuteri Once daily
Begtrup et al.54 
(2013)
Denmark 24 131 (97/34) I: 31.6 ± 10.1 
P: 29.4 ± 8.6
I: 54 
P: 44
Rome III All Probiotic MS L. paracasei, L. acidophilus 
and B. lactis
Twice daily in 
capsules
Choi et al.33 
(2011)
Korea 4 74 (37/37) I: 40.2 ± 13.1 
P: 40.6 ± 12.9
I: 34 
P: 33
Rome II IBS-D 
and 
IBS-M
Probiotic SS S. boulardii Twice daily in 
capsules
Drouault-
Holowacz et al.44 
(2008) 
France 4 100 (24/76) I: 47.0 ± 14.0 
P: 44.0 ± 14.0
I: 48 
P: 52
Rome II All Probiotic MS B. longum, L. acidophilus, 
Lactococcus lactis and 
Streptococcus thermophilus
Once daily in 
powder sachets
Ducrotté et al.36 
(2012)
India 4 214 (151/63) I: 36.5 ± 12.1 
P: 38.4 ± 13.1
I: 108 
P: 106
Rome III All Probiotic SS L. plantarum Once daily in 
capsules
Guglielmetti et al.56 
(2011) 
Italy 4 122 (40/82) I: 36.7 ± 12.4 
P: 40.9 ± 12.8
I: 60 
P: 62
Rome III All Probiotic SS B. bifidum Once daily in 
capsules
Guyonnet et al.32 
(2007)
France 6 267 (199/68) I: 49.4 ± 11.4 
P: 49.2 ± 11.4
I: 135 
P: 132
Rome II IBS-C Probiotic MS B. animalis, S. thermophilus 
and L. delbrueckii
Twice daily in 
yoghurt
Hod et al.29 
(2017)
Israel 8 107 (0/107) I: 29.0 ± 4.0 
P: 30.0 ± 6.0
I: 54 
P: 53
Rome III IBS-D Probiotic MS L. rhamnosus, L. 
paracasei, L. plantarum, L. 
acidophilus, L. bulgaricus, 
L. lactis, B. bifidum, B. 
longum, B. breve, B. infantis 
and S. thermophilus
Twice daily in 
capsules
Ishaque et al.31 
(2018)
Bangladesh 16 360 (281/79) I: 32.2 ± 10.1 
P: 31.7 ± 9.7
I: 181 
P: 179
Rome III IBS-D Probiotic MS Bacillus subtilis, B. 
bifidum, B. breve, B. 
infantis, B. longum, L. 
acidophilus, L. delbrueckii, 
L. casei, L. plantarum, L. 
rhamnosus, L. helveticus, L. 
salivarius, L. lactis and S. 
thermophilus
Twice daily in 
capsules
Jafari et al.37 
(2014)
Iran 4 108 (43/65) I: 36.6 ± 12.1 
P: 36.8 ± 11.0
I: 54 
P: 54
Rome III All Probiotic MS B. animalis, L. acidophilus, 
L. delbrueckii and S. 
thermophilus
Twice daily in 
capsules
Kajander et al.49 
(2008)
Finland 20 86 (6/80) I: 50.0 ± 13.0 
P: 46.0 ± 13.0
I: 43 
P: 43
Rome II All Probiotic MS L. rhamnosus, 
Propionibacterium 
freudenreichii and B. 
animalis
Once daily in a 
milk product
Ki Cha et al.30 
(2012) 




Rome III IBS-D Probiotic MS L. acidophilus, L. 
plantarum, L. rhamnosus, 
B. breve, B. lactis, B. 
longum and S. thermophilus
Once daily in 
capsules
Lyra et al.55 
(2016)
Finland 12 262 (64/198) I: 47.2 ± 12.5 
P: 49.4 ± 12.9
I: 131 
P: 131
Rome III All Probiotic SS L. acidophilus Once daily in 
powder
Nobaek et al.41 
(2000) 
Sweden 4 51 (15/36) I: 51.0 ± 22.0 
P: 46.0 ± 19.0
I: 25 
P: 26
Rome I All Probiotic SS L. plantarum Once daily in a 
rosehip drink
Pineton de 
Chambrun et al.57 
(2015)
France 8 179 (25/154) I: 42.5 ± 12.5 
P: 45.4 ± 14
I: 86 
P: 93
Rome III All Probiotic SS S. cerevisiae Once daily in 
capsules
Preston et al.35 
(2018) 
USA 12 113 (45/68) I: 40.6 ± 13.4 
P: 39.9 ± 14.0
I: 76 
P: 37
Rome III All Probiotic MS L. acidophilus and L. 
rhamnosus
Twice daily in 
capsules
Roberts et al.52 
(2013) 
UK 4 179 (30/149) I: 44.7 ± 11.9 
P: 43.7 ± 12.8
I: 88 
P: 91
Rome III All Probiotic MS B. lactis, S. thermophilus 
and L. delbrueckii
Twice daily in a 
milk product
Shin et al.28 
(2018)
Korea 8 51 (22/29) I: 35.0 ± 5.0 
P: 38.0 ± 8.0
I: 24 
P: 27
Rome III IBS-D Probiotic SS L. gasseri Twice daily in 
capsules
SD = standard deviation; IBS = irritable bowel syndrome; I = intervention group; P = placebo group; FOO = fructooligosaccharides; PHGG = partially hydrolysed guar gum; D = diarrhoea; 
SS = single-strain; S. = Saccharomyces; L. = Lactobacillus; MS = multi-strain; B = Bifidobacterium; M = mixed condition; C = constipation.
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dobacterium and Saccharomyces species as well as 
Clostridium butyricum.26–28,33,34,36,39,41,43,55–58
Only one of the RCTs was single-blinded.39 The 
remaining trials employed a double-blinded design.26–38,40–58 
The method of randomisation was not explicitly mentioned 
in five trials (15.2%); this was therefore categorised as 
an unclear risk in the risk of bias assessment under the 
random sequence generation domain.32,35,41,43,46 Block 
randomisation and a random allocation table was used 
in 12 RCTs each.26,28–40,43,45,47–52,54–58 Computer-based 
or online randomisation so ftware was used in four 
trials.27,31,34,53 For all studies, the primary outcome 
analysis was based on the intention-to-treat paradigm, 
apart from two studies investigating probiotic products 
and one study investigating a synbiotic intervention.31,39,40
The efficacy results of the interventions versus a 
placebo were presented in 17 probiotic trials involving 
2,431 patients for probiotics and three prebiotic trials 
involving 250 patients, while none of the synbiotic 
trials investigated effects on global symptoms 
scores.26,30–35,41–43,46,48–54,56,58 The pooled outcomes of the 
probiotic RCTs indicated significant improvements in 
global symptoms scores (SMD = −0.32, 95% CI: −0.48 
to −0.15; P <0.001). However, significant heterogeneity 
was observed between studies (I2 = 72%; P <0.001). This 
improvement remained significant with probiotics 
containing multi-strains (SMD = −0.23, 95% CI: −0.44 
to −0.02; P = 0.030) and those using species of Bifido- 
bacterium (SMD = −0.77, 95% CI: −1.00 to −0.53; P <0.001) 
and Clostridium (SMD = −0.34, 95% CI: −0.62 to −0.06; 
P = 0.020) [Table 2]. 
Additionally, probiotics significantly improved global 
IBS symptom scores in studies with a sample size of 
<150 patients (SMD = −0.31, 95% CI: −0.52 to −0.10; 
P = 0.004) and >150 patients (SMD = −0.32, 95% CI: 
−0.57 to −0.06; P <0.001) as well as studies utilising 
Rome I (SMD = −1.17, 95% CI: −1.76 to −0.57; P <0.001), 
Rome II (SMD = −0.29, 95% CI: −0.53 to −0.05; P = 0.020) 
and Rome III (SMD = −0.28, 95% CI: −0.50 to −0.06; 
P = 0.010) diagnostic criteria. As for prebiotics, there 
was no significant effect on IBS symptoms using a 
random effects model (SMD = 0.59, 95% CI: −0.01 to 
1.19; P = 0.050). This lack of significance was also 
apparent in the subgroup analyses.
Abdominal pain scores were assessed in 29 RCTs, 
including 25 probiotics, one prebiotic and three synbiotic 
trials.26–33,36–41,43–50,52–58 In a pooled analysis, there were 
no significant differences concerning abdominal pain 
scores with probiotics as compared to a placebo 
(SMD = −0.18, 95% CI: −0.43 to 0.07; P = 0.150) with 
significant heterogeneity between studies (I2 = 92%; 
P <0.001). However, abdominal pain scores were reduced 
Table 1 (cont’d): Summary of randomised clinical trials assessing the efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of 
irritable bowel syndrome26–58
Simrén et al.47 
(2010)
Sweden 8 74 (52/22) I: 42.0 ± 15.0 
P: 44.0 ± 16.0
I: 37 
P: 37
Rome II All Probiotic MS L. paracasei, L. acidophilus 
and B. lactis
Once daily in 
fermented milk
Sisson et al.53 
(2014) 
UK 12 186 (129/57) I: 39.6 ± 10.5 
P: 36.8 ± 10.8
I: 124 
P: 62
Rome III All Probiotic MS L. rhamnosus, L. 
plantarum, L. acidophilus 
and Enterococcus faecium
Once daily in 
syrup
Søndergaard et al.48 
(2011)
Denmark 8 52 (13/39) I: 53.9 ± 14.0 
P: 48.5 ± 13.7
I: 27 
P: 25
Rome II All Probiotic MS L. paracasei, L. acidophilus 
and B. lactis
Once daily in 
fermented milk
Spiller et al.58 
(2016)
UK 12 379 (62/317) I: 45.3 ± 15.7 
P: 45.4 ± 14.1
I: 192 
P: 187
Rome III All Probiotic SS S. cerevisiae Twice daily in 
capsules




8 81 (2/79) I: 48.1 ± 13.5 
P: 47.3 ± 12.1
I: 54 
P: 27
Rome II All Probiotic SS L. plantarum Once daily in 
capsules
Sun et al.26 
(2018)
China 4 200 (116/84) I: 43.0 ± 12.5 
P: 44.9 ± 13.0
I: 105 
P: 95
Rome III IBS-D Probiotic SS Clostridium butyricum Thrice daily in 
capsules
Whorwell et al.43 
(2006)
UK 4 182 (0/182) I: 41.8 ± 1.1 
P: 42.4 ± 1.1
I: 90 
P: 92
Rome II All Probiotic SS B. infantis Once daily in 
capsules
Williams et al.46 
(2009) 
UK 8 52 (7/45) I: 40.0 ± 12.0 
P: 38.0 ± 11.0
I: 28 
P: 24
Rome II All Probiotic MS L. acidophilus, B. lactis and 
B. bifidum
Once daily in 
capsules
Cappello et al.45 
(2013) 
Italy 4 62 (21/41) I: 36.6 ± 2.2 
P: 40.8 ± 2.2
I: 32 
P: 32
Rome II All Synbiotic L. plantarum, L. 
rhamnosus, L. gasseri, L. 
acidophilus, L. salivarius, 
L. sporogenes, B. infantis, 
B. longum, S. termophilus 
and inulin
Twice daily in 
powder sachets
Rogha et al.38 
(2014) 
Iran 12 56 (12/44) I: 42.6 ± 12.8 
P: 37.7 ± 12.4
I: 23 
P: 33
Rome III All Synbiotic B. coagulans and FOO Once daily in 
tablets
Shavakhi et al.40 
(2014) 
Iran 2 129 (44/85) I: 36.1 ± 7.9 
P: 36.4 ± 10.5
I: 66 
P: 63
Rome II All Synbiotic L. casei, L. rhamnosus, L. 
acidophilus, L. delbrueckii 
ssp. bulgaricus, B. breve, B. 
longum, S. thermophilus 
and FOO
Twice daily in 
capsules
SD = standard deviation; IBS = irritable bowel syndrome; I = intervention group; P = placebo group; FOO = fructooligosaccharides; PHGG = partially hydrolysed guar gum; D = diarrhoea; 
SS = single-strain; S. = Saccharomyces; L. = Lactobacillus; MS = multi-strain; B = Bifidobacterium; M = mixed condition; C = constipation.
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significantly with probiotics containing Lactobacillus 
species (SMD = −0.71, 95% CI: −1.33 to −0.10; P = 0.020) 
and when the Rome I criteria were utilised (SMD = −1.65, 
95% CI: −2.29 to −1.00; P <0.001) [Table 3].
The one prebiotic RCT assessing abdominal pain 
scores compared partially-hydrolysed guar gum to a 
placebo.47 No significant improvement was observed 
in abdominal pain (SMD = 0.69, 95% CI: −0.28 to 
1.36; P = 0.810). However, different combinations of 
probiotics and prebiotics in the synbiotic RCTs resulted 
in significant abdominal pain amelioration compared to a 
placebo (SMD = −4.27, 95% CI: −7.73 to −0.80; P = 0.020); 
in addition, the difference remained significant in 
trials employing the Rome III diagnostic criteria 
(SMD = −11.24, 95% CI: −13.46 to −9.01; P <0.001).
Regarding other IBS symptoms, the pooled effects 
of the probiotic trials showed no significant improve- 
ments in bloating and urgency scores. However, there 
was a trend of flatulence alleviation, with the effects 
nearing statistical significance (SMD = −0.68, 95% 
CI: −1.38 to 0.01; P = 0.050). Furthermore, a subgroup 
analysis revealed promising outcomes for distinct 
symptoms with certain single-strain probiotics. Specif- 
ically, probiotics containing Saccharomyces improved 
bloating (SMD = −0.20, 95% CI: −0.37 to −0.03; P = 0.020), 
while those containing Lactobacillus improved flatulence 
(SMD = −1.84, 95% CI: −2.43 to −1.25; P <0.001) and 
those containing Bifidobacterium improved urgency 
(SMD = −0.55, 95% CI: −0.85 to −0.26; P <0.001) in 
several RCTs.27,33,41,43,58 In one trial, a synbiotic inter- 
vention incorporating inulin and several probiotic strains 
significantly improved scores for both flatulence (SMD = 
−1.84, 95% CI: −2.43 to −1.25; P <0.001) and urgency 
(SMD = −0.70, 95% CI: −1.21 to −0.20; P = 0.006).45
In general, the use of probiotics did not significantly 
improve QOL scores, except in two trials involving 
Lactobacillus strains (SMD = 0.57, 95% CI: 0.21 to 
0.94; P = 0.020).28,34 Similarly, most of the prebiotic and 
synbiotic interventions did not affect QOL, although 
one prebiotic trial noted improvements following a 
12-week regimen of partially-hydrolysed guar gum.50 
As for the frequency of adverse events, a pooled risk 
analysis revealed no significant differences between 
patients receiving different types of interventions and 
those receiving a placebo (RR = 1.17, 95% CI: 0.98 to 
1.40; P = 0.080; I2 = 0%).
Discussion
While various pharmalogical treatments are available 
to alleviate the symptoms of IBS, such as tricyclic anti- 
depressants, antispasmodics and selective serotonin 
reuptake inhibitors, non-pharmalogical options are 
needed in order to improve efficacy of treatment and 
mitigate the risk of adverse events.59 Probiotics, pre- 
biotics and synbiotics are potentially promising appr- 
oaches of altering gut microbiota and alleviating symptoms 
of functional bowel disorders. The current article presents 
a systematic review and meta-analysis of recent 
RCTs evaluating the efficacy and safety of probiotics, 
prebiotics and synbiotics in the context of IBS. 
The findings of the present analysis indicate that 
probiotics had the most robust effect on improving 
global IBS symptoms, particularly those containing 
multi-strains and Bifidobacterium species. Additionally, 
Lactobacillus-containing probiotic products helped to 
significantly reduce specific symptoms (i.e. abdominal 
pain and flatulence) and improve the QOL of patients. 
Intriguingly, when probiotics were combined with 
prebiotics in synbiotic formulations, they also exhibited 
beneficial effects on urgency, abdominal pain and 
flatulence. 
Probiotics have significant effects on the integrity 
of the GI epithelium, which is maintained via tight 
junction (TJ) proteins. Zyrek et al. observed that pro- 
biotics containing the Escherichia coli strain Nissle 
1917 promoted the expression and redistribution of 
the ZO-2 protein to cellular contact sites in order to 
ultimately stabilise TJ proteins and preserve cellular 
morphology.60 Another species, L. plantarum, utilised 
in various RCTs as a component of single- and multi-
strain probiotic formulations, stimulates the expression 
of important TJ proteins (ZO-1, ZO-2, cingulin and 
occludin), leading to a remarkable enhancement in 
intestinal barrier functionality.29–31,34,36,41,45,53 These 
regulatory mechanisms eventually stabilise GI functions 
against pathogenic bacteria and limit the development 
of increased intestinal permeability, a factor likely 
involved in the pathogenesis of IBS.61
Bowel movement, another relevant target for IBS 
patients, could also be regulated via probiotic-cont- 
aining products. In a recent meta-analysis of RCTs 
involving patients with constipation, Miller et al. found 
that probiotics containing Lactobacillus or Bifido- 
bacterium species increased stool frequency and reduced 
intestinal transit time.62 In the present analysis, 
Lactobacillus-containing products resulted in signif- 
icant pain reduction, which may have contributed to 
QOL improvement. Indeed, Lactobacillus species are 
often reported as beneficial for abdominal pain in 
functional GI disorders.63,64 Although the exact mechanism 
of pain in IBS is as yet unclear, it is possible this 
symptom is mediated via persistent low-grade 
intestinal inflammation and changes in the quantity of 
gut microbiota.65
Overall, the act of altering the gut microbiota 
via the administration of probiotics seems to yield 
beneficial results for general IBS symptoms. This 
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could be further supported by the use of synbiotics; 
in the present analysis, this type of intervention 
resulted in significant improvements in abdominal 
pain, urgency and flatulence. The synbiotics were 
primarily composed of the most common probiotic 
strains (Lactobacillus and Bifidobacterium).40,45 On 
the other hand, the benefits of prebiotics (e.g. fruct- 
ooligosaccharides and partially-hydrolysed guar gum) 
seem to be less apparent.42,50,51 Indeed, the role of 
prebiotics in alleviating IBS symptoms is controversial 
since most of them are fermentable oligosaccharides, 
disaccharides, monosaccharides and polyols. Such 
compounds, including fructans and fructose, are 
poorly absorbed in the small intestine and undergo 
fermentation, exacerbating IBS symptoms.66,67
In terms of methodologies, the RCTs included in 
the current analysis were of moderate-to-high quality, 
with the majority employing a double-blind design. 
Moreover, a rigorous search strategy was used based 
on several keyword combinations in order to identify 
the most relevant studies. Minimal limits for sample 
sizes and methodological considerations were based 
on previous recommendations so that the findings 
would be reliable.24 Importantly, despite variations 
in the version used and the lack of trials utilising the 
latest criteria (Rome IV), all trials employed a unified 
diagnostic tool.
Previous systematic reviews and meta-analyses 
have confirmed the effectiveness and safety of probiotics 
for IBS patients.66 However, such analyses have failed to 
provide reliable recommendations regarding specific 
bacterial strains. In the present analysis, Lactobacillus 
and Bifidobacterium species resulted in significant 
benefits; these strains are therefore recommended by 
the authors. Supporting evidence exists, indicating 
that alterations in these species have been previously 
reported in IBS patients.68–70 Moreover, unlike other 
recently-published meta-analyses on this topic, the 
current article presents insight into the effect of 
synbiotics, showing that this type of intervention 
results in a significant ameliorating effect on IBS 
symptoms.71,72 In addition, to the best of the authors’ 
knowledge, this is the first meta-analysis to assess the 
effects of these formulations on QOL. 
Nonetheless, the present analysis was not without 
limitations. The majority of the RCTs included in the 
analysis assessed adherence to regimens qualitatively 
via verbal questioning. In addition, while patients were 
instructed to maintain their usual dietary patterns, no 
formal dietary assessment was performed; as such, 
the confounding effect of nutritional variables was not 
taken into consideration. Moreover, although it is the 
authors’ belief that the duration of interventions should 
be greater than four weeks, 13 trials (39.4%) did not meet 
this threshold.26,33,36,37,39–41,43–45,51,52,56 Therefore, longer 
follow-up periods are warranted in future studies. 
Furthermore, the effects of probiotics on specific 
subgroups of patients are unclear; for instance, the 
impact on those with IBS-D is conflicting, while little 
is known about the outcomes on patients with other 
IBS subtypes.26–31 Hence, future trials incorporating 
specific IBS subtypes are recommended. 
Another important limitation of the present meta- 
analysis was the failure to determine the exact sources 
of heterogeneity between studies. The authors suggest 
that consistent methodological designs, such as unified 
symptomatic assessment scores, should be used in 
future studies on this topic. Moreover, it is vital to 
highlight the low number of prebiotic studies identified 
in this review, since this limitation may interfere with 
the interpretation of pertinent outcomes. Finally, in 
terms of safety outcomes, it was difficult to determine 
whether repeatedly-reported side-effects (such as 
abdominal pain, diarrhoea, nausea, flatulence and 
heartburn) were due to the interventions or the 
disease itself because of symptom overlap. Therefore, 
the exact relationship between the interventions and 
such symptoms was unclear. 
Conclusion
The findings of this systematic review and meta-
analysis indicate that probiotics and synbiotics have 
the potential to alleviate global IBS symptoms. More 
specifically, products containing Lactobacillus species 
significantly reduced abdominal pain and flatulence 
scores and improved QOL, while urgency and other 
general symptoms were alleviated by Bifidobacterium-
containing formulations. Therefore, preparations cont- 
aining multi-strains of these bacterial species might be 
beneficial. However, there was significant inter-study 
heterogeneity, which warrants cautious interpretation 
of these findings. Future studies on this topic should 
employ longer follow-up periods, unify symptomatic 
assessment scores, monitor dietary patterns and clin- 
ically assess patient adherence to the interventions. 
References
1. Koloski NA, Talley NJ. Irritable bowel syndrome. In: Goldman MB, 
Troisi R, Rexrode KM, Eds. Women and Health, 2nd ed. Cambridge, 
Massachusetts, USA: Academic Press, 2012. Pp. 1353–66.
2. Drossman DA, Richter JE, Talley N, Thompson G, Corazziari E, 
Whitehead W. The functional gastrointestinal disorders: Diagnosis, 
pathophysiology and treatment - A multinational consensus. New 
York, USA: Little, Brown and Co., 1994.
3. Defrees DN, Bailey J. Irritable bowel syndrome: Epidemiology, 
pathophysiology, diagnosis, and treatment. Prim Care 2017; 
44:655–71. https://doi.org/10.1016/j.pop.2017.07.009.
Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome 
A systematic review and meta-analysis
e22 | SQU Medical Journal, February 2020, Volume 20, Issue 1
4. Lovell RM, Ford AC. Global prevalence of and risk factors for 
irritable bowel syndrome: A meta-analysis. Clin Gastroenterol 
Hepatol 2012; 10:712–21.e4. https://doi.org/10.1016/j.cgh.2012.02.029.
5. Drossman DA, Corazziari E, Talley N, Thompson W, Whitehead W. 
Rome II: The functional gastrointestinal disorders, 2nd ed. 
McLean, Virginia, USA: Degnon Associates Inc., 2000.
6. Drossman DA, Corazziari E, Delvaux M, Eds. Rome III: The 
functional gastrointestinal disorders, 3rd ed. McLean, Virginia, 
USA: Degnon Associates Inc., 2006.
7. Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE, 
Eds. Rome IV: Functional gastrointestinal disorders - Disorders 
of gut-brain interaction, 4th ed. Raleigh, North Carolina, USA: 
Rome Foundation, 2016.
8. Kavanagh RG, O’Grady J, Carey BW, O’Connor OJ, Maher MM. 
Review of the role of abdominal imaging in irritable bowel 
syndrome. World J Radiol 2018; 10:143–9. https://doi.org/10.43 
29/wjr.v10.i11.143.
9. Abd-El Khalek Abd-ALRazek A, Fahmy DM. Diagnostic value 
of diffusion-weighted imaging and apparent diffusion coefficient 
in assessment of the activity of Crohn disease: 1.5 or 3 T. J Comput 
Assist Tomogr 2018; 42:688–96. https://doi.org/10.1097/RCT.00 
00000000000754.
10. O’Malley D. Immunomodulation of enteric neural function in 
irritable bowel syndrome. World Journal of Gastroenterology: 
WJG. 2015 Jun 28; 21(24):7362.
11. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable 
bowel syndrome—a meta-analysis. American Journal of Gastro- 
enterology. 2006 Aug 1; 101(8):1894-9.
12. Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. 
The Microbiome and Irritable Bowel Syndrome–A Review on 
the Pathophysiology, Current Research and Future Therapy. 
Frontiers in microbiology. 2019; 10:1136.
13. Ringel Y, Ringel-Kulka T. The intestinal microbiota and irrit- 
able bowel syndrome. J Clin Gastroenterol 2015; 49:S56–9. 
https://doi.org/10.1097/mcg.0000000000000418.
14. König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, 
Mercenier A, et al. Human intestinal barrier function in health 
and disease. Clin Transl Gastroenterol 2016; 7:e196. https://doi.
org/10.1038/ctg.2016.54.
15. Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, Pistiki A, 
Pimentel M. Small intestinal bacterial overgrowth is assoc- 
iated with irritable bowel syndrome and is independent of 
proton pump inhibitor usage. BMC Gastroenterol 2016; 16:67. 
https://doi.org/10.1186/s12876-016-0484-6.
16. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. 
The gut microbiota and irritable bowel syndrome: Friend or 
foe? Int J Inflam 2012; 2012:151085. https://doi.org/10.1155/20 
12/151085.
17. Shimura S, Ishimura N, Mikami H, Okimoto E, Uno G, Tamagawa Y, 
et al. Small intestinal bacterial overgrowth in patients with 
refractory functional gastrointestinal disorders. J Neurogastro- 
enterol Motil 2016; 22:60–8. https://doi.org/10.5056/jnm15116.
18. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, 
Barbatzas C, Pimentel M. The prevalence of overgrowth by 
aerobic bacteria in the small intestine by small bowel culture: 
Relationship with irritable bowel syndrome. Dig Dis Sci 2012; 
57:1321–9. https://doi.org/10.1007/s10620-012-2033-7.
19. Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered 
molecular signature of intestinal microbiota in irritable bowel 
syndrome patients compared with healthy controls: A systematic 
review and meta-analysis. Dig Liver Dis 2017; 49:331–7. https://
doi.org/10.1016/j.dld.2017.01.142.
20. Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, 
et al. Prevalence, risk factors, and outcomes of irritable bowel 
syndrome after infectious enteritis: A systematic review and meta- 
analysis. Gastroenterology 2017; 152:1042–54.e1. https://doi.org/ 
10.1053/j.gastro.2016.12.039.
21. Floch MH. Probiotics and prebiotics. Gastroenterol Hepatol 
(N Y) 2014; 10:680–1. 
22. Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and 
synbiotics- A review. J Food Sci Technol 2015; 52:7577–87. 
https://doi.org/10.1007/s13197-015-1921-1.
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 
Preferred reporting items for systematic reviews and meta-
analyses: The PRISMA statement. PLoS Med 2009; 6:e1000097. 
https://doi.org/10.1371/journal.pmed.1000097.
24. Mazurak N, Broelz E, Storr M, Enck P. Probiotic therapy of the 
irritable bowel syndrome: Why is the evidence still poor and 
what can be done about it? J Neurogastroenterol Motil 2015; 
21:471–85. https://doi.org/10.5056/jnm15071.
25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, 
et al. The Cochrane Collaboration’s tool for assessing risk of bias 
in randomised trials. BMJ 2011; 343:d5928. https://doi.org/10.1 
136/bmj.d5928.
26. Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, et al. The effect 
of Clostridium butyricum on symptoms and fecal microbiota 
in diarrhea-dominant irritable bowel syndrome: A randomized, 
double-blind, placebo-controlled trial. Sci Rep 2018; 8:2964. 
https://doi.org/10.1038/s41598-018-21241-z.
27. Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, 
et al. Cytokine and clinical response to Saccharomyces boulardii 
therapy in diarrhea-dominant irritable bowel syndrome: A rand- 
omized trial. Eur J Gastroenterol Hepatol 2014; 26:630–9. 
https://doi.org/10.1097/meg.0000000000000094.
28. Shin SP, Choi YM, Kim WH, Hong SP, Park JM, Kim J, et al. 
A double blind, placebo-controlled, randomized clinical trial 
that breast milk derived-Lactobacillus gasseri BNR17 mitigated 
diarrhea-dominant irritable bowel syndrome. J Clin Biochem 
Nutr 2018; 62:179–86. https://doi.org/10.3164/jcbn.17-73.
29. Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, 
et al. A double-blind, placebo-controlled study to assess the 
effect of a probiotic mixture on symptoms and inflammatory 
markers in women with diarrhea-predominant IBS. Neuro- 
gastroenterol Motil 2017; 29. https://doi.org/10.1111/nmo.13037.
30. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, 
Joon Kim H, et al. The effect of a multispecies probiotic mixture 
on the symptoms and fecal microbiota in diarrhea-dominant 
irritable bowel syndrome: A randomized, double-blind, placebo- 
controlled trial. J Clin Gastroenterol 2012; 46:220–7. https://
doi.org/10.1097/MCG.0b013e31823712b1.
31. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A rand- 
omized placebo-controlled clinical trial of a multi-strain pro- 
biotic formulation (Bio-Kult®) in the management of diarrhea-
predominant irritable bowel syndrome. BMC Gastroenterol 
2018; 18:71. https://doi.org/10.1186/s12876-018-0788-9.
32. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, 
Mercier CH, et al. Effect of a fermented milk containing Bifi- 
dobacterium animalis DN-173 010 on the health-related quality 
of life and symptoms in irritable bowel syndrome in adults in 
primary care: A multicentre, randomized, double-blind, cont- 
rolled trial. Aliment Pharmacol Ther 2007; 26:475–86. https://
doi.org/10.1111/j.1365-2036.2007.03362.x.
33. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A 
randomized, double-blind, placebo-controlled multicenter trial 
of saccharomyces boulardii in irritable bowel syndrome: Effect 
on quality of life. J Clin Gastroenterol 2011; 45:679–83. https://
doi.org/10.1097/MCG.0b013e318204593e.
34. Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Rand- 
omized clinical trial: Effect of Lactobacillus plantarum 299 v 
on symptoms of irritable bowel syndrome. Nutrition 2014; 
30:1151–7. https://doi.org/10.1016/j.nut.2014.02.010.
Mohammad Z. Asha and Sundos F. H. Khalil
Review | e23
35. Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, 
Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus 
casei LBC80R and Lactobacillus rhamnosus CLR2 improve 
quality-of-life and IBS symptoms: A double-blind, randomised, 
placebo-controlled study. Benef Microbes 2018; 9:697–706. 
https://doi.org/10.3920/bm2017.0105.
36. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus 
plantarum 299v (DSM 9843) improves symptoms of irritable 
bowel syndrome. World J Gastroenterol 2012; 18:4012–18. 
https://doi.org/10.3748/wjg.v18.i30.4012.
37. Jafari E, Vahedi H, Merat S, Momtahen S, Riahi A. Therapeutic 
effects, tolerability and safety of a multi-strain probiotic in 
Iranian adults with irritable bowel syndrome and bloating. 
Arch Iran Med 2014; 17:466–70. 
38. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a 
synbiotic containing Bacillus coagulans in treatment of irritable 
bowel syndrome: A randomized placebo-controlled trial. Gastro- 
enterol Hepatol Bed Bench 2014; 7:156–63. 
39. Amirimani B, Nikfam S, Albaji M, Vahedi S, Nasseri-Moghaddam S, 
Sharafkhah M, et al. Probiotic vs. placebo in irritable bowel 
syndrome: A randomized controlled trial. Middle East J Dig Dis 
2013; 5:98–102.
40. Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, 
Tayebi A, et al. The effects of multi-strain probiotic compound 
on symptoms and quality-of-life in patients with irritable bowel 
syndrome: A randomized placebo-controlled trial. Adv Biomed 
Res 2014; 3:140. https://doi.org/10.4103/2277-9175.135157.
41. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alter- 
ation of intestinal microflora is associated with reduction in abdo- 
minal bloating and pain in patients with irritable bowel syndrome. 
Am J Gastroenterol 2000; 95:1231–8. https://doi.org/10.1111/
j.1572-0241.2000.02015.x.
42. Olesen M, Gudmand-Hoyer E. Efficacy, safety, and tolerability 
of fructooligosaccharides in the treatment of irritable bowel 
syndrome. Am J Clin Nutr 2000; 72:1570–5. https://doi.org/10. 
1093/ajcn/72.6.1570.
43. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, 
O’Mahony L, et al. Efficacy of an encapsulated probiotic 
Bifidobacterium infantis 35624 in women with irritable bowel 
syndrome. Am J Gastroenterol 2006; 101:1581–90. https://doi.
org/10.1111/j.1572-0241.2006.00734.x.
44. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, 
Dray X, Marteau P. A double blind randomized controlled 
trial of a probiotic combination in 100 patients with irritable 
bowel syndrome. Gastroenterol Clin Biol 2008; 32:147–52. 
https://doi.org/10.1016/j.gcb.2007.06.001.
45. Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. 
A randomised clinical trial (RCT) of a symbiotic mixture in 
patients with irritable bowel syndrome (IBS): Effects on 
symptoms, colonic transit and quality of life. Int J Colorectal Dis 
2013; 28:349–58. https://doi.org/10.1007/s00384-012-1552-1.
46. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, 
Barker ME, et al. Clinical trial: A multistrain probiotic 
preparation significantly reduces symptoms of irritable bowel 
syndrome in a double-blind placebo-controlled study. Aliment 
Pharmacol Ther 2009; 29:97–103. https://doi.org/10.1111/j.13 
65-2036.2008.03848.x.
47. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, 
et al. Clinical trial: The effects of a fermented milk containing 
three probiotic bacteria in patients with irritable bowel 
syndrome - A randomized, double-blind, controlled study. Ali- 
ment Pharmacol Ther 2010; 31:218–27. https://doi.org/10.11 
11/j.1365-2036.2009.04183.x.
48. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, 
Ekesbo R. Effects of probiotic fermented milk on symptoms and 
intestinal flora in patients with irritable bowel syndrome: A 
randomized, placebo-controlled trial. Scand J Gastroenterol 2011; 
46:663–72. https://doi.org/10.3109/00365521.2011.565066.
49. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, 
Rasmussen M, Järvenpää S, et al. Clinical trial: Multispecies 
probiotic supplementation alleviates the symptoms of irritable 
bowel syndrome and stabilizes intestinal microbiota. Aliment 
Pharmacol Ther 2008; 27:48–57. https://doi.org/10.1111/j.136 
5-2036.2007.03542.x.
50. Niv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T, et al. 
Randomized clinical study: Partially hydrolyzed guar gum 
(PHGG) versus placebo in the treatment of patients with 
irritable bowel syndrome. Nutr Metab (Lond) 2016; 13:10. 
https://doi.org/10.1186/s12986-016-0070-5.
51. Azpiroz F, Dubray C, Bernalier-Donadille A, Cardot JM, 
Accarino A, Serra J, et al. Effects of scFOS on the composition 
of fecal microbiota and anxiety in patients with irritable bowel 
syndrome: A randomized, double blind, placebo controlled 
study. Neurogastroenterol Motil 2017; 29. https://doi.org/10.11 
11/nmo.12911.
52. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A 
randomised controlled trial of a probiotic ‘functional food’ in the 
management of irritable bowel syndrome. BMC Gastroenterol 
2013; 13:45. https://doi.org/10.1186/1471-230X-13-45.
53. Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clin- 
ical trial: A liquid multi-strain probiotic vs. placebo in the irritable 
bowel syndrome--A 12 week double-blind study. Aliment Pharmacol 
Ther 2014; 40:51–62. https://doi.org/10.1111/apt.12787.
54. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, 
Jarbøl DE. Long-term treatment with probiotics in primary 
care patients with irritable bowel syndrome--A randomised, 
double-blind, placebo controlled trial. Scand J Gastroenterol 
2013; 48:1127–35. https://doi.org/10.3109/00365521.2013.825314.
55. Lyra A, Hillilä M, Huttunen T, Männikkö S, Taalikka M, Tennilä J, 
et al. Irritable bowel syndrome symptom severity improves 
equally with probiotic and placebo. World J Gastroenterol 2016; 
22:10631–42. https://doi.org/10.3748/wjg.v22.i48.10631.
56. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised 
clinical trial: Bifidobacterium bifidum MIMBb75 significantly 
alleviates irritable bowel syndrome and improves quality 
of life--A double-blind, placebo-controlled study. Aliment 
Pharmacol Ther 2011; 33:1123–32. https://doi.org/10.1111/j.1365-
2036.2011.04633.x.
57. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, 
Justen P, et al. A randomized clinical trial of Saccharomyces cere- 
visiae versus placebo in the irritable bowel syndrome. Dig Liver 
Dis 2015; 47:119–24. https://doi.org/10.1016/j.dld.2014.11.007.
58. Spiller R, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, 
Cazaubiel M, et al. Randomized double blind placebo-contr- 
olled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable 
bowel syndrome: Improvement in abdominal pain and bloating 
in those with predominant constipation. United European Gastro- 
enterol J 2016; 4:353–62. https://doi.org/10.1177/2050640615602571.
59. Munjal A, Dedania B, Cash B. Update on pharmacotherapy for 
irritable bowel syndrome. Curr Gastroenterol Rep 2019; 21:25. 
https://doi.org/10.1007/s11894-019-0692-7.
60. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, 
Schmidt MA. Molecular mechanisms underlying the probiotic 
effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC- 
zeta redistribution resulting in tight junction and epithelial 
barrier repair. Cell Microbiol 2007; 9:804–16. https://doi.org/10.1 
111/j.1462-5822.2006.00836.x.
61. Slyepchenko A, Maes M, Jacka FN, Köhler CA, Barichello T, 
McIntyre RS, et al. Gut microbiota, bacterial translocation, 
and interactions with diet: Pathophysiological links between 
major depressive disorder and non-communicable medical 
comorbidities. Psychother Psychosom 2017; 86:31–46. https://
doi.org/10.1159/000448957.
62. Miller LE, Ouwehand AC, Ibarra A. Effects of probiotic-
containing products on stool frequency and intestinal transit 
in constipated adults: Systematic review and meta-analysis of 
randomized controlled trials. Ann Gastroenterol 2017; 30:629–39. 
https://doi.org/10.20524/aog.2017.0192.
Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome 
A systematic review and meta-analysis
e24 | SQU Medical Journal, February 2020, Volume 20, Issue 1
63. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lacto- 
bacillus rhamnosus GG for abdominal pain-related functional 
gastrointestinal disorders in childhood. Aliment Pharmacol Ther 
2011; 33:1302–10. https://doi.org/10.1111/j.1365-2036.2011.04665.x.
64. Jadrešin O, Hojsak I, Mišak Z, Kekez AJ, Trbojević T, Ivković L, 
et al. Lactobacillus reuteri DSM 17938 in the treatment of 
functional abdominal pain in children: RCT study. J Pediatr 
Gastroenterol Nutr 2017; 64:925–9. https://doi.org/10.1097/
mpg.0000000000001478.
65. Chichlowski M, Rudolph C. Visceral pain and gastrointestinal 
microbiome. J Neurogastroenterol Motil 2015; 21:172–81. 
https://doi.org/10.5056/jnm15025.
66. Ooi SL, Correa D, Pak SC. Probiotics, prebiotics, and low 
FODMAP diet for irritable bowel syndrome - What is the 
current evidence? Complement Ther Med 2019; 43:73–80. 
https://doi.org/10.1016/j.ctim.2019.01.010.
67. Yan YL, Hu Y, Gänzle MG. Prebiotics, FODMAPs and dietary 
fiber — Conflicting concepts in development of functional 
food products? Curr Opin Food Sci 2018; 20:30–7. https://doi.
org/10.1016/j.cofs.2018.02.009.
68. Lacy BE. Hot topics in primary care: Role of the microbiome 
in disease - Implications for treatment of irritable bowel 
syndrome. J Fam Pract 2017; 66:S40–5. 
69. Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut 
dysbiosis and irritable bowel syndrome: The potential role of 
probiotics. J Infect 2018; 76:111–20. https://doi.org/10.1016/j.
jinf.2017.12.013.
70. Menees S, Chey W. The gut microbiome and irritable bowel 
syndrome. F1000Res 2018; 7:F1000. https://doi.org/10.12688/
f1000research.14592.1.
71. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, 
et al. Efficacy of prebiotics, probiotics, and synbiotics in irri- 
table bowel syndrome and chronic idiopathic constipation: Syst- 
ematic review and meta-analysis. Am J Gastroenterol 2014; 
109:1547–61. https://doi.org/10.1038/ajg.2014.202.
72. Ford AC, Harris LA, Lacy BE, Quigley EM, Moayyedi P. Syst- 
ematic review with meta-analysis: The efficacy of prebiotics, 
probiotics, synbiotics and antibiotics in irritable bowel synd- 
rome. Aliment Pharmacol Ther 2018; 48:1044–60. https://doi.
org/10.1111/apt.15001.
